{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:04:40Z","timestamp":1763096680176,"version":"3.45.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Hyperkalemia is a common and potentially life-threatening electrolyte abnormality in patients with heart failure, particularly among those with diabetes or chronic kidney disease. It often results from the use of renin\u2013angiotensin\u2013aldosterone system inhibitors, which, while improving survival, increase serum potassium levels. Elevated potassium produces cardiotoxic effects, often recognized by characteristic electrocardiographic changes. Acute management focuses on stabilizing cardiac membranes with intravenous calcium and shifting potassium intracellularly through insulin-dextrose, \u03b2\u2082-agonists, or sodium bicarbonate, with caution to avoid fluid overload. Potassium elimination may be achieved using diuretics or hemodialysis when refractory. For chronic management, newer potassium-binding agents such as patiromer and sodium zirconium cyclosilicate offer improved safety and efficacy compared with traditional resins, enabling the continuation and up-titration of renin\u2013angiotensin\u2013aldosterone system inhibitors. These therapies support optimal neurohormonal blockade, improve adherence, and reduce morbidity and mortality in heart failure.<\/jats:p>","DOI":"10.1097\/crd.0000000000001127","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:00:46Z","timestamp":1763096446000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Managing Hyperkalemia in Heart Failure Patients: A Systematic Review"],"prefix":"10.1097","author":[{"given":"Mahesh","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Research, Mayo Clinic, Jacksonville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimsha","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima Safi","family":"Arslan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahnoor","family":"Niaz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, MedStar Health, Georgetown University School of Medicine, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saifullah","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, MedStar Health, Georgetown University School of Medicine, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fnu","family":"Aperna","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Advent Health, Orlando, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"R1-20251114","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3390\/nu8070444","article-title":"Potassium intake, bioavailability, hypertension, and glucose control.","volume":"8","author":"Stone","year":"2016","journal-title":"Nutrients"},{"key":"R2-20251114","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis.","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R3-20251114","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure.","volume":"113","author":"Roger","year":"2013","journal-title":"Circ Res"},{"key":"R4-20251114","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1097\/CCM.0b013e31818f222b","article-title":"Management of severe hyperkalemia.","volume":"36","author":"Weisberg","year":"2008","journal-title":"Crit Care Med"},{"key":"R5-20251114","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/01.CIR.47.2.408","article-title":"Relation of electrolyte disturbances to cardiac arrhythmias.","volume":"47","author":"Fisch","year":"1973","journal-title":"Circulation"},{"key":"R6-20251114","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/00325481.1974.11713789","article-title":"Electrolytes and the electrocardiograim.","volume":"55","author":"Surawicz","year":"1974","journal-title":"Postgrad Med"},{"key":"R7-20251114","doi-asserted-by":"crossref","first-page":"241","DOI":"10.31083\/j.rcm.2020.02.8","article-title":"Hyperkalemia in heart failure: current treatment and new therapeutic perspectives.","volume":"21","author":"Min\u00e0","year":"2020","journal-title":"Rev Cardiovasc Med"},{"key":"R8-20251114","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes.","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"R9-20251114","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CRD.0000000000000286","article-title":"Mineralocorticoid receptor antagonist use in heart failure with reduced ejection fraction and end-stage renal disease patients on dialysis: a literature review.","volume":"28","author":"Bhinder","year":"2020","journal-title":"Cardiol Rev"},{"key":"R10-20251114","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/ndt\/gfz263","article-title":"Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population.","volume":"36","author":"Wetmore","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"R11-20251114","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3949\/ccjm.84a.17056","article-title":"Diagnosis and treatment of hyperkalemia.","volume":"84","author":"Palmer","year":"2017","journal-title":"Cleve Clin J Med"},{"key":"R12-20251114","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11897-019-00425-2","article-title":"Acute management of hyperkalemia.","volume":"16","author":"Liu","year":"2019","journal-title":"Curr Heart Fail Rep"},{"key":"R13-20251114","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"R14-20251114","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"R15-20251114","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"R16-20251114","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"R17-20251114","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/HCO.0000000000000709","article-title":"Hyperkalemia in heart failure.","volume":"35","author":"Sidhu","year":"2020","journal-title":"Curr Opin Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:00:48Z","timestamp":1763096448000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001127","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]}}}